Public Offerings, Clinical Tests, and Financial Results- Research Report on InterMune, Emergent BioSolutions, ImmunoGen,

 Public Offerings, Clinical Tests, and Financial Results- Research Report on
     InterMune, Emergent BioSolutions, ImmunoGen, Sequenom, and Intrexon

PR Newswire

NEW YORK, November 13, 2013

NEW YORK, November 13, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting InterMune
Inc. (NASDAQ: ITMN), Emergent BioSolutions, Inc. (NYSE: EBS), ImmunoGen Inc.
(NASDAQ: IMGN), Sequenom Inc. (NASDAQ: SQNM), and Intrexon Corporation (NYSE:
XON). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

InterMune Inc. Research Report

On November 5, 2013, InterMune Inc. (InterMune) announced that it has agreed
to sell 6.5 million shares of its common stock in an underwritten public
offering at a price of $13.00 per share to the public. InterMune informed that
it has granted the underwriters a 30-day option to purchase up to an
additional 975,000 shares of common stock regarding the offering. The Company
stated that it estimates net proceeds from the offering to be approximately
$79.6 million (assuming no exercise of the underwriters' option to purchase
additional shares of common stock), excluding underwriting discounts and
commissions and estimated offering expenses. InterMune added that it plans to
use the net proceeds from the offering to fund the commercialization of
Esbriet and its ASCEND clinical trial for U.S. registration of Esbriet, to
advance the company's strategic initiatives, clinical trials supporting the
use of Esbriet in idiopathic pulmonary fibrosis (IPF), expanding anti-fibrotic
research program, and for general corporate purposes. Lastly, the Company
stated that it expects to close this transaction around November 12, 2013. The
Full Research Report on InterMune Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/dd8c_ITMN]

--

Emergent BioSolutions, Inc. Research Report

On November 7, 2013, Emergent BioSolutions Inc. (Emergent BioSolutions)
reported its Q3 2013 financial results with total revenues of $89.1 million
compared to $66.6 million in Q3 2012. Net income attributable to the Company
totaled $13.5 million or $0.36 per diluted share compared to $6.6 million or
$0.18 per diluted share in Q3 2012. Daniel J. Abdun-Nabi, President and CEO of
Emergent BioSolutions commented, "We are very pleased with our financial
results during the third quarter and first nine months of 2013." He concluded,
"Finally, we continue to pursue acquisitions of additional products or
companies that leverage our competencies and drive us toward achieving the
goals identified in our growth plan." For full-year 2013 the Company
anticipates total revenues to be in the range of $300 million to $310 million
and net income to be between $25 million to $30 million. The Full Research
Report on Emergent BioSolutions, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/b2cc_EBS]

--

ImmunoGen Inc. Research Report

On November 5, 2013, ImmunoGen, Inc. (ImmunoGen) announced the initiation of
clinical testing with its EGFR-targeting antibody-drug conjugate (ADC),
IMGN289, which is designed to bind to and kill cancer cells that highly
express EGFR, also known as HER1. Dr. Charles Morris, Executive Vice President
and Chief Development Officer stated, "There is a lot of excitement around
IMGN289. It is an antibody-drug conjugate, or ADC, to a well-known target,
EGFR, and a potential new treatment for several types of cancers - including
squamous cell lung and head and neck cancers - that have very limited
treatment options today. We are delighted to now be gaining clinical
experience with this promising new agent." The Full Research Report on
ImmunoGen Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/11c8_IMGN]

--

Sequenom Inc. Research Report

On November 7, 2013, Sequenom, Inc. (Sequenom) reported its Q3 2013 financial
results. Total revenues for the quarter were of $44 million, representing a
92.3% YoY increase. Net loss totaled $28.1 million or $0.24 per diluted share
in Q3 2013 compared to $30.2 million or $0.26 per share in Q3 2012. Commenting
on the results, Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom
stated, "We are proud to report record-breaking revenues for the third
quarter, which primarily resulted from the continued adoption of the
MaterniT21™ PLUS test. In October, we marked the second anniversary of the
launch of Sequenom Laboratories industry-leading noninvasive prenatal test
(NIPT) by announcing additional content for our MaterniT21 PLUS test. We began
to report the presence of subchromosomal microdeletions and autosomal
trisomies for chromosomes 16 and 22." The Full Research Report on Sequenom
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d291_SQNM]

--

Intrexon Corporation Research Report

On November 7, 2013, Intrexon Corp. (Intrexon) reported its Q3 2013 financial
results with revenues of $6.1 million compared to $2.9 million in Q3 2012.
According to the Company, the increase in revenue resulted primarily from the
recognition of deferred revenue for upfront payments received from five
collaborations signed by Intrexon between October 1, 2012 and September 30,
2013, and one milestone payment received in October 2012. Net income
attributable to common shareholders during the quarter was at $8.3 million or
$0.15 per diluted share compared to a net loss attributable to common
shareholders of $26 million or 4.66 per diluted share in Q3 2012. The Full
Research Report on Intrexon Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/cb5c_XON]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.

1.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
2.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
3.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.